Thiazolidinedione safety
admin December 4th, 2007
Following review, The European Medicines Agency has concluded that the benefits of the thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) continue to outweigh their risks in the approved indications. They have also suggested that further studies should be carried out in order to increase the amount of information about the safety of these agents. [PDF Press Release].
The MHRA has also put up a page of material related to this decision, cardiovascular disorders, eye disorders and fracture risks. The issue is also covered in this month’s Drug Safety Update.